6-bromo-8-(morpholin-4-yl)-1,2,3,4-tetrahydro-1,5-naphthyridine, 95.0%, 500mg

10H-Spiro[acridine-9,9'-fluorene], 97%, 10g

3-Fluoro-5-methoxybenzaldehyde, 95.0%, 5g

1,1,2-Trichloro-2,3,3-trifluorocyclobutane, 97.0%, 5g

2-Chloro-4,5-dimethylpyrimidine, 97%, 100mg

Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 5-[[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)-6-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-, 2mg

4-(2-AMINO-4-CYANO-PHENYL)-BUTYRIC ACID ETHYL ESTER, 90.0%, 500mg

3-(4-FLUORO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE, 95%, 5g

Silver sulphide, min. 98%, 10 g, glass packaging

Ethyl 2-acetylthiazole-4-carboxylate, 97.0%, 10g

4-methyl-2-phenyl-5-pyrimidinecarboxylic acid, 95.0%, 5g

GC capillary column ROTI®Cap-5, 25 m, 0.53 mm, 1.00 µm, 1 Piece(s)

Methyl 2-(pyridin-3-yl)acetate, 95.0%, 100g